Modality
Gene Therapy
MOA
CD3xCD20
Target
FcRn
Pathway
Proteasome
Thymoma
Development Pipeline
Preclinical
~Nov 2021
→ ~Feb 2023
Phase 1
~May 2023
→ ~Aug 2024
Phase 2
Nov 2024
→ Oct 2027
Phase 2Current
NCT07095021
1,674 pts·Thymoma
2024-11→2027-10·Recruiting
1,674 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-10-031.5y awayPh2 Data· Thymoma
Trial Timeline
2025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P2
Recruit…
Catalysts
Ph2 Data
2027-10-03 · 1.5y away
Thymoma
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07095021 | Phase 2 | Thymoma | Recruiting | 1674 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn | |
| Sovafutibatinib | Moderna | Approved | FcRn | |
| ITC-1028 | Intra-Cellular | Phase 2 | BCMA |